Mesoblast Limited SEC filings document its foreign-issuer reporting through Form 6-K submissions that incorporate Australian Securities Exchange announcements, Appendix 4C activity reports, press releases, and R&D presentation materials. The disclosures cover Ryoncil® commercialization, operating cash activity, and clinical programs built around allogeneic mesenchymal lineage stromal cell products.
The filing record also includes ASX notices for director interests, cessation of securities, unquoted equity securities, and applications for quotation of securities. These materials describe capital-structure changes, governance reporting, product and platform updates, and the company’s Form 20-F foreign private issuer framework.
Mesoblast Limited reported strong progress for the quarter ended March 31, 2026. Lead product Ryoncil® generated gross sales of US$35.3 million and net revenues of US$30.3 million, with first-year launch revenues approaching US$100 million. Net operating cash spend was reduced to US$4.1 million, supported by customer receipts of US$34.6 million and tight cost control.
The company ended the quarter with US$121.8 million in cash and cash equivalents and reported total available funding of US$171.8 million, equivalent to an estimated 41.8 quarters of funding at the current cash burn rate. Mesoblast achieved its patient recruitment target in a pivotal phase 3 trial of rexlemestrocel‑L for chronic low back pain and received FDA clearance to begin a label‑extension trial of Ryoncil in adults with steroid‑refractory acute graft versus host disease, as well as IND clearance for a registrational trial in Duchenne muscular dystrophy. The company also acquired an exclusive worldwide license to a patented CAR technology platform to develop next‑generation mesenchymal stromal cell products for inflammatory and autoimmune diseases.
Mesoblast Limited reported strong progress for the quarter ended March 31, 2026. Lead product Ryoncil® generated gross sales of US$35.3 million and net revenues of US$30.3 million, with first-year launch revenues approaching US$100 million. Net operating cash spend was reduced to US$4.1 million, supported by customer receipts of US$34.6 million and tight cost control.
The company ended the quarter with US$121.8 million in cash and cash equivalents and reported total available funding of US$171.8 million, equivalent to an estimated 41.8 quarters of funding at the current cash burn rate. Mesoblast achieved its patient recruitment target in a pivotal phase 3 trial of rexlemestrocel‑L for chronic low back pain and received FDA clearance to begin a label‑extension trial of Ryoncil in adults with steroid‑refractory acute graft versus host disease, as well as IND clearance for a registrational trial in Duchenne muscular dystrophy. The company also acquired an exclusive worldwide license to a patented CAR technology platform to develop next‑generation mesenchymal stromal cell products for inflammatory and autoimmune diseases.
Mesoblast Ltd director Lynette Elizabeth Cobley filed an initial Form 3 showing her existing equity stake. She reports 30,000 Ordinary Shares held directly and 33,000 Ordinary Shares held indirectly through Synergy Finance Pty Ltd as trustee for her self-managed superannuation fund. She also holds an option over 200,000 Ordinary Shares at an exercise price of $1.72 per share, expiring on May 9, 2032. According to the footnote, these options were granted on May 10, 2025 and vest in three annual tranches through 2028.
Mesoblast Ltd director Lynette Elizabeth Cobley filed an initial Form 3 showing her existing equity stake. She reports 30,000 Ordinary Shares held directly and 33,000 Ordinary Shares held indirectly through Synergy Finance Pty Ltd as trustee for her self-managed superannuation fund. She also holds an option over 200,000 Ordinary Shares at an exercise price of $1.72 per share, expiring on May 9, 2032. According to the footnote, these options were granted on May 10, 2025 and vest in three annual tranches through 2028.
Mesoblast Limited reported that its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease has reached its patient recruitment target of at least 300 participants. Patients receive a single intra-discal injection of rexlemestrocel-L or sham control and are followed for 12 months.
The study aims to confirm earlier Phase 3 results that showed clinically meaningful pain and opioid-use reductions for up to three years. Top-line data are expected in mid-CY2027, with a planned U.S. FDA Biologics License Application filing in Q3 CY2027. Rexlemestrocel-L holds Regenerative Medicine Advanced Therapy designation, and Mesoblast sees potential peak year revenue above US$10 billion at single-digit market penetration, given over 7 million affected patients in the U.S.
Mesoblast Limited reported that its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease has reached its patient recruitment target of at least 300 participants. Patients receive a single intra-discal injection of rexlemestrocel-L or sham control and are followed for 12 months.
The study aims to confirm earlier Phase 3 results that showed clinically meaningful pain and opioid-use reductions for up to three years. Top-line data are expected in mid-CY2027, with a planned U.S. FDA Biologics License Application filing in Q3 CY2027. Rexlemestrocel-L holds Regenerative Medicine Advanced Therapy designation, and Mesoblast sees potential peak year revenue above US$10 billion at single-digit market penetration, given over 7 million affected patients in the U.S.
Mesoblast Limited furnished a Form 6-K that forwards several Australian Securities Exchange appendices on new equity issues and changes in securities, including a detailed change of director’s interest notice for Gregory George.
The notice shows an increase in his indirect holdings after on-market purchases by related holders. These trades added 70,000 American Depositary Shares (ADS), with each ADS representing 10 ordinary shares, and 7,210,962 ordinary shares. The filing states total cash consideration of US$11,429,969.84 for the ADS and ordinary shares purchased. Following the transactions, his indirect interests rose to 12,855,154 ordinary shares, 14,485,410 ADS, and 6,830,602 warrants to acquire ordinary shares, while his direct positions were unchanged.
Mesoblast Limited furnished a Form 6-K that forwards several Australian Securities Exchange appendices on new equity issues and changes in securities, including a detailed change of director’s interest notice for Gregory George.
The notice shows an increase in his indirect holdings after on-market purchases by related holders. These trades added 70,000 American Depositary Shares (ADS), with each ADS representing 10 ordinary shares, and 7,210,962 ordinary shares. The filing states total cash consideration of US$11,429,969.84 for the ADS and ordinary shares purchased. Following the transactions, his indirect interests rose to 12,855,154 ordinary shares, 14,485,410 ADS, and 6,830,602 warrants to acquire ordinary shares, while his direct positions were unchanged.
Mesoblast Limited reported that it has acquired an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform designed to enhance its mesenchymal stromal cell (MSC) therapies. The CAR constructs are intended to improve targeted homing of MSCs to inflamed tissues, aiming to increase potency in inflammatory and autoimmune diseases.
The intellectual property, originally developed at Mayo Clinic and published in Nature Biomedical Engineering, may support new or stronger indications such as ulcerative colitis, Crohn's disease, Lupus Nephritis and other B cell–driven conditions. Mesoblast obtained the rights via acquiring a startup formed to advance the CAR-MSC technology, paying with ASX ordinary shares, and Mayo Clinic will provide in-kind support including GMP manufacturing activities.
Mesoblast Ltd director and ten percent owner George Gregory reported a series of indirect open-market purchases of Ordinary Shares. Between April 4 and April 10, related accounts for Grant George and James George, each granting power of attorney to Dr. George, bought a combined 7,910,962 Ordinary Shares at prices between $1.41 and $1.48 per share. The filing shows indirect holdings in these accounts increasing to as many as 13,586,890 Ordinary Shares following the transactions. A footnote explains that these Ordinary Shares are represented by American Depositary Shares, with each ADS reflecting a beneficial interest in 10 Ordinary Shares, and that reported prices are already adjusted to the per‑Ordinary‑Share level.
Mesoblast Ltd director and ten percent owner George Gregory reported a series of indirect open-market purchases of Ordinary Shares. Between April 4 and April 10, related accounts for Grant George and James George, each granting power of attorney to Dr. George, bought a combined 7,910,962 Ordinary Shares at prices between $1.41 and $1.48 per share. The filing shows indirect holdings in these accounts increasing to as many as 13,586,890 Ordinary Shares following the transactions. A footnote explains that these Ordinary Shares are represented by American Depositary Shares, with each ADS reflecting a beneficial interest in 10 Ordinary Shares, and that reported prices are already adjusted to the per‑Ordinary‑Share level.
Mesoblast Limited used its R&D Day to highlight rapid commercial progress with Ryoncil and a late‑stage pipeline targeting multi‑billion‑dollar inflammatory indications. Ryoncil net revenue is approaching US$100 million since its U.S. launch last year, with Q3 FY26 gross revenue of US$35 million and net revenue of US$30 million.
The company reported H1 FY26 Ryoncil gross profit of US$44 million against US$7 million in direct selling costs, and a cash balance of US$130 million at December 31 2025, supported by a new US$125 million term loan. Management targets FY26 net revenue of US$110–120 million and aims to double Ryoncil revenue.
Mesoblast is advancing Phase 3 programs for chronic low back pain and inflammatory heart failure, each with stated total addressable markets above US$10 billion, plus label extensions for Ryoncil in adult SR‑aGvHD and Duchenne muscular dystrophy. Next‑generation CAR‑ and oncolytic virus‑engineered MSC platforms and manufacturing upgrades are intended to support long‑term growth.
Mesoblast Limited used its R&D Day to highlight rapid commercial progress with Ryoncil and a late‑stage pipeline targeting multi‑billion‑dollar inflammatory indications. Ryoncil net revenue is approaching US$100 million since its U.S. launch last year, with Q3 FY26 gross revenue of US$35 million and net revenue of US$30 million.
The company reported H1 FY26 Ryoncil gross profit of US$44 million against US$7 million in direct selling costs, and a cash balance of US$130 million at December 31 2025, supported by a new US$125 million term loan. Management targets FY26 net revenue of US$110–120 million and aims to double Ryoncil revenue.
Mesoblast is advancing Phase 3 programs for chronic low back pain and inflammatory heart failure, each with stated total addressable markets above US$10 billion, plus label extensions for Ryoncil in adult SR‑aGvHD and Duchenne muscular dystrophy. Next‑generation CAR‑ and oncolytic virus‑engineered MSC platforms and manufacturing upgrades are intended to support long‑term growth.
Mesoblast Ltd director William Murray Burns filed an initial Form 3 showing his beneficial holdings in the company. The filing lists several option awards over Ordinary Shares with exercise prices ranging from $0.36 to $1.81 per share and expirations between 2026 and 2031. It also reports direct ownership of 226,250 Ordinary Shares as of the reporting date. These entries reflect existing positions rather than new purchases or sales.
Mesoblast Ltd director William Murray Burns filed an initial Form 3 showing his beneficial holdings in the company. The filing lists several option awards over Ordinary Shares with exercise prices ranging from $0.36 to $1.81 per share and expirations between 2026 and 2031. It also reports direct ownership of 226,250 Ordinary Shares as of the reporting date. These entries reflect existing positions rather than new purchases or sales.
Mesoblast Ltd CEO and Managing Director Silviu Itescu reported his existing ownership of Ordinary Shares and stock options. He directly holds 67,756,838 Ordinary Shares and has additional indirect holdings through entities associated with him. He also holds multiple option awards over Ordinary Shares with exercise prices from 0.3500 to 2.4600 per share, expiring between 2026 and 2032.
Mesoblast Ltd CEO and Managing Director Silviu Itescu reported his existing ownership of Ordinary Shares and stock options. He directly holds 67,756,838 Ordinary Shares and has additional indirect holdings through entities associated with him. He also holds multiple option awards over Ordinary Shares with exercise prices from 0.3500 to 2.4600 per share, expiring between 2026 and 2032.
Mesoblast Ltd director George Gregory filed an initial ownership report listing his existing holdings in the company. The filing shows direct and indirect positions in ordinary shares, American Depositary Shares, warrants, and stock options with various exercise prices and expirations. A footnote explains that each ADS represents a beneficial interest in 10 ordinary shares.